Filing Flows › Comparisons › JUNS vs ONCO
Jupiter Neurosciences vs Onconetix: JUNS and ONCO compared
Jupiter Neurosciences is the larger company: $24K of revenue in its latest quarter (Q2 2026) against $17K for Onconetix (Q2 2026).
Where the money goes: JUNS and ONCO
Jupiter Neurosciences (JUNS) · Q2 2026
Jupiter Neurosciences, Q2 2026: revenue $24K, net loss $2.3M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
Onconetix (ONCO) · Q2 2026
Onconetix, Q2 2026: revenue $17K (-84% year over year), net loss $2.9M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Jupiter Neurosciences (JUNS) | Onconetix (ONCO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $24K | $17K |
| Revenue growth, Y/Y | — | -84% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.3M | −$2.9M |
| Operating cash flow | −$2.3M | −$1.9M |
Questions
Which is bigger, Jupiter Neurosciences or Onconetix?
Jupiter Neurosciences is the larger company: $24K of revenue in its latest quarter (Q2 2026) against $17K for Onconetix (Q2 2026).
More: Jupiter Neurosciences earnings · how Jupiter Neurosciences makes money · Onconetix earnings · how Onconetix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.